Johnson & Johnson Caught Up in Risperdal Scandal

Controversy is swirling about Johnson & Johnson’s attempts to bankroll a health institute focusing on treating children with the controversial drug Risperdal. While doctors can prescribe drugs for uses not approved by the FDA, pharmaceutical companies are prohibited from marketing such drugs for non-approved uses. That’s the controversy surrounding J&J and the antipsychotic drug Risperdal.
Internal company emails circulating in J&J’s Janssen unit dating from 2001-02 raise issues about the pharmaceutical company’s behavior, especially since Risperdal was not officially approved by the FDA since 2007.
Risperdal has been a controversial antipsychotic drug since its approval. It has been at the center of a debate concerning the use or overuse of such drugs among young children.